Ab­b­Vie's pso­ri­a­sis drug Skyrizi beats out Am­gen's block­buster in PhIV head-to-head study

Ab­b­Vie’s pso­ri­a­sis drug Skyrizi beat out Am­gen’s Ote­zla in a Phase IV head-to-head ef­fi­ca­cy and safe­ty study test­ing both treat­ments in adult pa­tients with mod­er­ate …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.